Cost of chickenpox in Canada: Part II. Cost of complicated cases and total economic impact

Pediatrics

Volumn 104, Issue 1 I, 1999, Pages 7-14

  Law, Barbara ^a   Fitzsimon, Catherine ^b   Ford Jones, Lee ^c   McCormick, John ^b   Rivière, Marc ^b   Halperin, Scott ^d   Wang, Elaine ^c   Lebel, Marc ^e   Scheifele, David ^f   MacDonald, Noni ^g   Mills, Elaine ^h   Morris, Robert ⁱ   Déry, Pierre ^j   Jadavji, Taj ^k   Vaudry, Wendy ^l   Duclos, Philippe ^m   DeLage, Gilles ⁿ  

^a UNIVERSITY OF MANITOBA   (Canada)

^b IQVIA   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d IWK HEALTH CENTRE   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f Vaccine Evaluation Center   (Canada)

^g CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^h MONTREAL CHILDREN S HOSPITAL   (Canada)

ⁱ Division of Cardiology   (Canada)

^j LAVAL UNIVERSITY   (Canada)

^k ALBERTA CHILDREN'S HOSPITAL   (Canada)

^l UNIVERSITY OF ALBERTA   (Canada)

^m Bureau of Infectious Diseases   (Canada)

ⁿ CANADIAN PAEDIATRIC SOCIETY   (Canada)

more..

Author keywords

Canada; Chickenpox; Complications; Cost

Indexed keywords

ARTICLE; CANADA; CHICKENPOX; CHILD; CONTROLLED STUDY; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PRODUCTIVITY;

EID: 0033013795     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.104.1.7     Document Type: Article

References (16)

1. McKendrick MW. Acyclovir for childhood chickenpox. Cost is unjustified. Br Med J. 1995;310:108-109
2. Preblud SR. Varicella. Complications and Costs. Pediatrics. 1986; 78(suppl):728-735
3. Guess HA, Broughton DD, Melton LJ, Kurland LT. Population-based studies of varicella complications. Pediatrics. 1986;78(suppl):723-727
4. Takahashi M, Gershon AA. Varicella vaccine. In: Plotkin SA, Mortimor EA, eds. Vaccines. Philadelphia. PA: WB Saunders; 1994:387-418
5. Holmes SJ, Reef S, Hadler SC, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1996;45:1-36
6. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1994. MMWR Morb Mortal Wkly Rep. 1994;43:80
7. Varughese PV. Chickenpox in Canada. Can Med Assoc J. 1988;138: 133-134
8. Huse DM, Meissner CH, Lacey MJ, Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr. 1994;124:869-874
9. Lieu TA, Cochi SL, Black SB, et al. Cost effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271: 375-381
10. Preblud SR, Orenstein WA, Koplan JP, et al. A benefit cost analysis of a childhood varicella vaccination programme. Postgrad Med J. 1985; 61(suppl 4):17-22
11. Scheifele DS. IMPACT monitoring network: a better mousetrap. Can J Infect Dis. 1993;4:194-195
12. Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. J Pediatr. 1997;130:759-765
13. Law B, Fitzsimon C, Ford-Jones L, et al. Cost of chickenpox in Canada: Part I. Cost of uncomplicated cases. Pediatrics. 1999;104:1-6
14. Cochi SL, Broome CV, Hightower AW. Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine. JAMA. 1985; 253:521-529
15. Weber DJ, Rutala WA, Parham C. Impact and costs of varicella prevention in a university hospital. Am J Public Health. 1988;78:19-23
16. Rivière M, Tretiak R, Levinton C, et al. Economic benefits of a routine second dose of combined measles, mumps and rubella vaccine in Canada. Can J Infect Dis. 1997;8:257-264